Cancer Immunotherapeutics In the News
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
Susanne Gray Warner, M.D., a surgical oncologist at City of Hope, on what you need to know regarding pancreatic cancer.
Skin cancer is the most common kind of cancer. It takes many forms, but even melanoma, the rarest and most aggressive form, has a nearly 100 percent cure rate. City of Hope's Kim Margolin, M.D., discusses melanoma diagnosis and treatment.
These three City of Hope physicians have dramatically different backgrounds, but they share a devotion to helping people and saving lives and now they share in the generosity of longtime City of Hope philanthropists Norman and Melinda Payson. Vijay Trisal, M.D., Jeffrey Weitzel, M.D., and John Chan, M.D., were recent invested through gifts made from the Payson family.
After many complications, City of Hope lymphoma patient Lucy found renewed hope after an immunotherapy clinical trial.
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.
When Kim Margolin, M.D., talks about her work, the words are packed with information and pour out with energy and passion. It’s easy to see what makes her an internationally recognized leader in the fight against melanoma.
FDA approves tisagenlecleucel (commercial name Kymriah) CAR T cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
City of Hope researchers use novel technology to add new functionalities to already potent proteins.
CAR T Cells Save Chuck Fata's Life
City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.
City of Hope today announced that it is a certified treatment center to administer tisagenlecleucel (commercial name Kymriah) chimeric antigen receptor (CAR) T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration (FDA) – to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.
Reflections on Reuniting, One Year Later
Often unrecognized are the countless folks who work in the spaces between the lab and the clinic — people responsible for doing everything from manufacturing CAR T cells to gaining federal approval for new trials.
With undergrad training in horticulture, a master’s degree in entomology and a Ph.D. in agriculture, Javier Gordon Ogembo, Ph.D., more or less stumbled into medicine — and the field is lucky to have him.
From Cuba to Calcutta, across Asia, throughout Europe and North and South America, City of Hope's Yuman Fong, M.D's go-anywhere philosophy has taken him everywhere. Some visits last only a few hours. But each carries a specific purpose.
In memory of Ben and Beverly Horowitz, longtime chief executive officer and first lady of City of Hope, their family has donated $1 million to City of Hope to help advance groundbreaking CAR-T cell immunotherapy research to combat cancer.
CEA remains one of the most widely used clinical markers of cancer. As the diverse roles of CEA and CEACAMs, have grown clearer, researchers at City of Hope are working on a new wave of clinical tools and therapies.
As an affiliate of City of Hope, TGen will use its genomics expertise to chart a path to greater precision in CAR T therapies for cancer patients.
Christine Brown, Ph.D., co-leads the T Cell Therapeutics Research Laboratory, along with Stephen J. Forman, M.D., which to date has treated more than 100 patients in seven clinical trials, with aggressive goals of opening four new clinical studies within the year.
Xiuli Wang, Ph.D., is at the forefront of one of the most exciting breakthroughs in cancer treatment, chimeric antigen receptor (CAR) T cell therapy.
New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.